다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
大韓本草學會誌 = The Korea journal of herbology, v.28 no.4, 2013년, pp.83 - 92
이호일 (대구한의대학교 한의과대학 외관과학교실) , 정지윤 (대구한의대학교 한의과대학 방제학교실) , 황보민 (대구한의대학교 한의과대학 외관과학교실) , 구세광 (대구한의대학교 한의과대학 해부학교실) , 김영우 (대구한의대학교 한의과대학 방제학교실) , 지선영 (대구한의대학교 한의과대학 외관과학교실)
AI-Helper
Objectives : Lespedeza Cuneata has been used to treat leukorrhea, asthma, stomach pain, diarrhea, acute mastitis, in Korean traditional medicine. According to recent studies, Lespedeza Cuneata has antioxidation, hypoglycemia, cell protective, insulin secretion, whitening, corpora cavernosa smooth mu...
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 염증이란 무엇인가? | 염증은 세균감염이나, 화학적 물질 등에 의한 자극에 대한 생체조직의 방어반응의 하나로 조직변질, 순환장애와 삼출, 조직 증식의 세 가지를 병발하는 복잡한 병변으로 알려져 있으며 Alzheimers disease, asthma, psoriasis, atherosclerosis, rheumatoid arthritis, atopic dermatitis, sarcoidosis 등 많은 질병의 원인으로 생각되고 있다1-3). | |
| 夜關門은 어떤 병증의 치료에 활용되는가? | 비수리, 공겡이대 등으로 불리는 夜關門 (Lespedeza Cuneata G. Don)은 苦辛凉하며, 補肝腎, 益肺陰, 散瘀消腫의 효능이 있어 遺精, 遺尿, 白濁, 白帶下, 喘息, 胃痛, 勞傷, 小兒疳積, 泄瀉, 打撲傷, 視力減退, 赤目, 急性乳腺炎 등의 치료에 활용된다4-9). | |
| 염증반응의 조절을 위한 NO억제에 대한 연구가 활발하게 이루어지고 있는데, 이는 NO의 어떤 특성 때문인가? | NO는 세포내에서 혈관조절, 숙주면역, 방어, 신호전달 등에서 중요한 역할을 하지만, 과량의 NO는 septic shock, 뇌경색, 당뇨, 퇴행성신경질환 등을 유발하기도 한다26-32). 이런 까닭에 NO 생성 억제제는 염증반응의 조절제로서의 가능성 때문에 NO억제에 대한 연구가 활발하게 이루어지고 있다. |
Park CY, Ryu HJ. Inflammation and Obesity. J Korean Soc Endocrinol. 2004 ; 19(2) : 97-108.
Nathan C. Points of control in inflammation. Nature. 2002 ; 420(6917) : 846-52.
Tracey KJ. The inflammatory reflex. Nature. 2002 ; 420(6917) : 853-9.
Kim CM, Shin MG, Ahn DG, Lee GS, Kang BS, Kang SS. The Chinese Herbal Dictionary. Seoul : Jeongdam. 1997 : 2770-3.
Kim TH, Ryu SN. Antioxidant activity of methanol extract from aerial parts in Lespedeaza cuneata G. Don. Korean J Crop Sci. 2008 ; 53 : 121-23.
Kwon DJ, Kim JK, Ham YH, Bae YS. Flavone glycosides from the aerial parts of Lespedeaza cuneata G. Don. J Korean Soc Appl Biol Chem. 2007 ; 50 : 344-7.
Kim TJ. Wild Flowers and Resources Plants in Korea (2). Seoul : SNU Press. 2008 : 457.
Chang JK. Wild Plants for Health. Seoul : Nexus books. 1996 : 72.
Ahn DG. Color Pictures of Korean Medicinal Herbs. Seoul : Gyohaksa. 1998 : 111.
Matsuura S, Iinuma M, Ito E, Takami H, Kagei K. Studies on the constituents of the useful plants. Ⅷ. The Constituents of Lespedeaza cuneata G. Don. Yakugaku Zasshi. 1978 ; 98 : 1542-4.
Atsushi N, Kazuko H. C-Glycoylflavones in Lespedeaza cuneata. Chem Pharm Bull. 1980 ; 28 : 964-5.
Deng F, Chang J, Zhang JS. New flavonoids and other constituents from Lespedeaza cuneata. J Asian Nat Prod Res. 2007 ; 9(6-8) : 655-8.
Kim SJ, Kim DW. Antioxidative Activity of Hot Water and Ethanol Extracts of Lespedeaza cuneata. Korean J Food Preserv. 2007 ; 14(3) : 332-5.
Kim MS, Min OJ, Rhyu DY. Effect of Lespedeaza cuneata Extracts on diabetes and diabetic nephropathy. Korean J plant Res. 2008 ; 4 : 83.
Lee DS, Jeong GS, An RB, Bin Li, Erisa Byun, Kim YC. Search for plant extracts with protective effects of pancreatic beta cell against oxidative stress. Kor J Pharmacogn. 2008 ; 39(4) : 335-40.
Choi JS, Cho CS, Kim CJ. Cytoprotective Effect of Lespedeza Cuneata Extract on Glucose Toxicity. J Korean Oriental Med. 2010 ; 31(4) : 70-100.
Jung YH, Lim CH. Bioactivity of an Extract of Lespedezea Cuneata G. Don to Rabbit Corpus Cavernosum Smooth Muscle Tone. Jour Agri Sci. 2005 ; 32(1) : 63-70.
Cho EJ, Lee SG, Kim DO. The effect of Lespedeza Cuneata extract for antioxidative and whitening effect. J Life Resources & Science Res. 2009 ; 28 : 34-8.
Cho EJ, Chu HM, Jung CH, Eom SH, Hur HJ, Kim DR. Effect of Phenolic Extract of Dry Leaves of Lespedeza cuneata G. Don on Antioxidant Capacity and Tyrosinase Inhibition. Kor J Hort Sci Technol. 2011 ; 29(4) : 358-65.
Kim HD, Cho HR, Moon SB, Shin HD, Yang KJ, Park BR, Jang HJ, Lim LS, Lee HS, Ku SK. Effect of exopolymers from Aureobasidum pullulans on formalin-induced chronic paw inflammation in mice. J Microbiol Biotechnol. 2006 ; 16 : 1954-60.
Delgado AV, McManus AT, Chambers JP. Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides. 2003 ; 37(6) : 355-61.
Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, Lotz M. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol. 1989 ; 142(1) : 144-7.
Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001 ; 159(2) : 387-97.
Charles AJ, Paul T, Mark W, Mark S. Immunobiology (5ed). New York : Garland. 2001 : 80.
Yun HY, Dawson VL and Dawson TM. Neurobiology of nitric oxide. Crit Rev Neurobiol. 1996 ; 10 : 291-316.
Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr. 2007 ; 137 : 1616S-20S.
Weisz A, Cicatiello I and Esumi H. Regulation of the mouse inducible-type nitric oxide synthase gene promoter by interferon-gamma, bacterical lipopolysaccharide and NG-monomethyl-L-arginene. Biochem J. 1996 ; 316 : 209-15.
McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF and Wahl SM. Suppression of arthritis by an inhibitor of nitic oxide synthase. J Exp Med. 1993 ; 178 : 749-754.
Seo WG, Pae HO, Oh GS, Chai KY, Yun YG, Kwon TO, Chung HT. Inhibitory effect of ethyl acetate fraction from Cudrania tricuspidata on the expression of nitric oxide synthase gene in RAW 264.7macrophages stimulated with interferon-and lipopolysaccharide. Gen Pharmacol. 2000 ; 35 : 21-8.
Chiou WF, Chou CJ, Chen CF. Camptothecin suppresses nitric oxide biosynthesis in RAW 264.7 macrophages. Life Sci. 2001 ; 69 : 625-35.
Lee BG, Kim SH, Zee OP, Lee KR, Lee HY, Han JW, Lee HW. Suppression of inducible nitric oxide synthase expression in RAW 264.7 macrophages by two-carboline alkaloids extracted from Melia azedarach. Eur J Pharmacol. 2000 ; 406 : 301-9.
Kawamata H, Ochiai H, Mantani N, Terasawa K. Enhanced expression of inducible nitric oxide synthase by Juzen-taiho-to in LPS-activated RAW264.7 cells, a murine macrophage cell line. Am J Chin Med. 2000 ; 28 : 217-26.
Posadas I, Terencio MC, Guillen I, Ferrandiz ML, Coloma J, Paya M, Alcaraz MJ. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2000 ; 361 : 98-106.
Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992 ; 6 : 3051-64.
Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006 ; 98(11) : 736-47.
Yang CH. Gastrointestinal disorders associated with non-steroidal anti-inflammatory drugs (NSAIDs). Dongguk Med. 2003 ; 10(2) : 190-9.
Lee AK, Sung SH, Kim YC, Kim SG. Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF- $\alpha$ and COX-2 expression by sauchinone effects on I- $\kappa{B}\alpha$ phosphorylation, C/EBP and AP-1 activation. Br J pharmacol. 2003 ; 139 : 11-20.
Patk HJ, Yoon SW, Yoon JW, Yoon HJ, Ko WS. Inhibitory Effect of Omisodok-eum on Secretion of NO in LPS-stimulated Mouse Peritoneal Macrophages. Korean J Orient Physiol Pathol. 2002 ; 16(2) : 921-7.
Shon GH, Kim SH. Antitumor Activity of Bupleuri Radix and Artemisiae capillaris Herba and Synergistic Effect with Anticancer Drugs. KOMS. 1995 ; 16(2) : 414-32.
Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF- $\kappa{B}1$ precursor protein and the activation of NF- $\kappa{B}$ . Cell. 1996 ; 78(5) : 773-85.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Free Access. 출판사/학술단체 등이 허락한 무료 공개 사이트를 통해 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.